BioSpace News Archive

To build its ophthalmology portfolio, Japan’s Otsuka Pharmaceuticals has teamed with RNA editing biotech Shape Therapeutics to develop adeno-associated virus gene therapies for ocular diseases.

As biosimilars and next-generation treatments for Crohn’s disease enter the market, AbbVie will be knocked from its place of longtime dominance, contends data and analytics firm GlobalData.

With a potential combined market value of $30 billion, BioSpace takes a deep dive into the Phase III data supporting Eisai and Biogen’s Leqembi and Eli Lilly’s investigational donanemab.

The companies have started a collaboration worth up to $3.4 billion to develop a portfolio of degrader-antibody conjugates, a potentially new class of antibodies that selectively kill cancer cells.

After its prostate cancer therapy was not included in Medicare’s initial drug price negotiation list, Astellas dismissed its Inflation Reduction Act lawsuit this week, while Illumina got new leadership.

Seeking to deepen its neurology and rare disease pipelines, AstraZeneca’s Alexion has joined forces with Verge Genomics to leverage its artificial intelligence platform in drug discovery and development.

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc. (Nasdaq: PSTV) (Plus), which expands the comprehensive laboratory services agreement between the two companies that was announced in June 2022.

Visus Therapeutics Inc. today announced that Ben Bergo, co-founder and chief executive officer, will present at the Baird 2023 Global Healthcare Conference on September 12th , 2023, at the InterContinental New York Barclay hotel.

Thermo Fisher Scientific Inc., the world leader in serving science, has been recognized by the R&D 100 Awards, honoring the top 100 revolutionary products in science and technology from around the world, for three unique innovations that aid researchers’ and scientists’ work in a variety of life science applications, including bioproduction and small-molecule analysis.

Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), today announces an antibody license agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd (‘Biocytogen’, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics.